{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"107.0","upperLimit":"204.0","value":"164.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the time from the date of first study treatment to first occurrence of documented progressive disease /relapse or death. Time from randomization until disease progression or death by Kaplan-Meier estimates","dispersionType":"95% Confidence Interval","groups":[{"description":"panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma","id":"OG000","title":"Panobinostat + Bortezomib & Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS)","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"days"}